公开(公告)号：US20230235413A1

公开(公告)日：2023-07-27

申请号：US18009731

申请日：2021-06-11

申请人： Universite Paris Cite ,  Assistance Publique - Hopitaux de Paris ,  Centre National de la Recherche Scientifique ,  INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Sorbonne Universite

发明人： Helene Pere ,  David Veyer ,  Valerie Taly ,  Pierre Laurent-Puig

IPC分类号： C12Q1/70 ,  C12Q1/6883 ,  C12Q1/686 ,  C12Q1/06

CPC分类号： C12Q1/70 ,  C12Q1/6883 ,  C12Q1/686 ,  C12Q1/06 ,  C12Q2600/156

摘要： The invention relates to methods for determining the severity of a disease caused by a coronavirus infection, comprising quantifying the level of cellular RNA of RNase P in a blood sample of a subject.

公开(公告)号：US20230210866A1

公开(公告)日：2023-07-06

申请号：US17905562

申请日：2021-03-10

申请人： UNIVERSITE CLAUDE BERNARD LYON 1 ,  INSERM (Institut National de la Sante et de la Recherche Medicale) ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) ,  ECOLE NORMALE SUPERIEURE DE LYON ,  SIGNIA THERAPEUTICS

发明人： Manuel ROSA-CALATRAVA ,  Olivier TERRIER ,  Mario Andres PIZZORNO ,  Aurelien TRAVERSIER ,  Blandine PADEY ,  Thomas JULIEN

IPC分类号： A61K31/554 ,  A61P31/14 ,  A61K31/7076 ,  A61K45/06

CPC分类号： A61K31/554 ,  A61K31/7076 ,  A61K45/06 ,  A61P31/14

摘要： The present invention relates to a pharmaceutical composition comprising Diltiazem in a suitable pharmaceutical carrier for its therapeutic use in the prevention and/or treatment of a viral infection caused by the SARS-CoV-2 virus, referred to as COVID-19 disease.

公开(公告)号：US11690856B2

公开(公告)日：2023-07-04

申请号：US16758292

申请日：2018-10-22

申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE D'AIX MARSEILLE

发明人： Pierre Szepetowski ,  Robin Cloarec ,  Sylvian Bauer ,  Nadine Bruneau

IPC分类号： A61K31/65 ,  A61P25/28 ,  A61K31/663

CPC分类号： A61K31/65 ,  A61K31/663 ,  A61P25/28

摘要： The present invention relates the field of CMV and CMV related diseases. Using a powerful rat model of CMV infection of the embryonic brain, the inventors have looked for the existence of postnatal neurological and neurosensory manifestations, and have tested whether the early pharmacological targeting of microglia during pregnancy impacts on postnatal phenotypes. Particularly, the inventors tested the clodronate and the doxycycline and showed that these compounds improve the postnatal outcome of the baby. Thus, the invention relates to a compound which modifies the microglia for use in the treatment of CMV related diseases in a subject in need thereof.

公开(公告)号：US20230165853A1

公开(公告)日：2023-06-01

申请号：US17910385

申请日：2022-01-13

申请人： ENYO PHARMA ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

发明人： FABIOLA TERZI ,  RAPHAËL DARTEIL ,  PIETRO SCALFARO ,  JACKY VONDERSCHER ,  HUGO GIRMA

IPC分类号： A61K31/496 ,  A61P13/12 ,  A61P1/16

CPC分类号： A61K31/496 ,  A61P13/12 ,  A61P1/16

摘要： The present invention relates to a method for treating chronic kidney diseases.

公开(公告)号：US20230135837A1

公开(公告)日：2023-05-04

申请号：US16650070

申请日：2018-09-27

申请人： CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE (CHRU) ,  UNIVERSITE DE LILLE ,  UNIVERSITE DU LITTORAL COTE D'OPALE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  TAIPEI MEDICAL UNIVERSITY

发明人： David DEVOS ,  Thierry BURNOUF ,  Jean-christophe DEVEDJIAN ,  Ming-Li CHOU ,  Flore GOUEL

IPC分类号： A61K35/19 ,  C12N5/078 ,  A61P25/28

摘要： The present invention relates on a process for preparing platelet lysate fraction, said process comprising the steps of: 1) providing a platelet lysate, 2) collecting from said platelet lysate a fraction wherein the components exhibit a maximum molecular weight of 100 kDa, on a specific platelet lysate fraction and its use as a drug.

公开(公告)号：US20230117384A1

公开(公告)日：2023-04-20

申请号：US17750705

申请日：2022-05-23

申请人： GENETHON ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  UNIVERSITE D'EVRY VAL D'ESSONNE

发明人： Saliha MAJDOUL ,  David FENARD

IPC分类号： C12N15/87 ,  C12N15/86 ,  C07K14/82 ,  A61K48/00 ,  C07K14/47

摘要： The present invention relates to peptides and compositions for use in improving transduction efficiency of viruses into target cells.

公开(公告)号：US11629192B2

公开(公告)日：2023-04-18

申请号：US16120514

申请日：2018-09-04

申请人： INSERM (Institut National de la Sante et de la Recherche Medicale) ,  Universite Paris Descartes ,  Fondation Imagine ,  Assistance Publique-Hopitaux de Paris (APHP) ,  Centre National de la Recherche Scientifique (CNRS) ,  Universite Grenoble Alpes ,  Commissariat a l'Energie Atomique et aux Energies Alternatives ,  Universite de Bourgogne

发明人： Zakia Belaid-Choucair ,  Olivier Hermine ,  Carmen Garrido-Fleury ,  Claude Cochet ,  Odile Filhol-Cochet ,  Renaud Seigneuric

IPC分类号： A61K31/00 ,  A61K39/00 ,  C07K16/28 ,  A61K38/17 ,  A61K31/4745 ,  A61K31/7105 ,  A61K31/713 ,  A61K39/395 ,  A61K45/06 ,  C12N15/113 ,  G01N33/566

摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the NRP-1/OBR signaling pathway.

公开(公告)号：US20230095683A1

公开(公告)日：2023-03-30

申请号：US17908925

申请日：2021-03-04

申请人： Institut National De Recherche Pour L'Agriculture, L'Alimentation et L'Environnement ,  ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS ,  SORBONNE UNIVERSITE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

发明人： HARRY SOKOL ,  ALLISON AGUS ,  CHLOÉ MICHAUDEL ,  JULIEN PLANCHAIS ,  PHILIPPE LANGELLA

IPC分类号： A61K35/741 ,  C12N1/20 ,  A61P1/00 ,  A61P3/00

摘要： The present invention relates to the preventive or curative treatment of metabolic syndrome and associated disorders, and inflammatory bowel diseases using Coprococcus bacteria and/or culture supernatants thereof.

公开(公告)号：US11596698B2

公开(公告)日：2023-03-07

申请号：US16628650

申请日：2018-07-06

申请人： GENETHON ,  UNIVERSITE D'EVRY-VAL-D'ESSONNE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)

发明人： Isabelle Richard ,  Evelyne Gicquel-Zouida ,  William Lostal

IPC分类号： A61K48/00 ,  A61P21/00 ,  C07K14/47 ,  C12N15/86 ,  A61K38/00

摘要： The present invention concerns synthetic polynucleotides encoding a human fukutin-related protein (FKRP) wherein the synthetic polynucleotides contain at least a mutation avoiding supplementary transcript(s) generated from frameshift start codon(s). The synthetic polynucleotides are useful, especially for treating a pathology linked to a FKRP deficiency or induced by a defect in α-dystroglycan (α-DG) glycosylation, such as LGMD2I.

公开(公告)号：US20230033268A1

公开(公告)日：2023-02-02

申请号：US17770641

申请日：2020-10-22

申请人： GENETHON ,  UNIVERSITE D'EVRY VAL D'ESSONNE ,  INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) ,  SORBONNE UNIVERSITE

发明人： PASQUALINA COLELLA ,  FRANCESCO PUZZO ,  FEDERICO MINGOZZI

IPC分类号： C07K7/08 ,  C12N15/86 ,  A61P3/00

摘要： The present invention relates to a nucleic acid molecule encoding a chimeric polypeptide comprising a peptide of interest fused to one or more heterologous moieties, wherein at least one of the heterologous moieties is a ligand of the Sortilin receptor. The invention also relates to a chimeric polypeptide encoded by said nucleic acid molecule and uses thereof.